stable angina pectoris
Cardiovascular · 2017–2018
No submission for this condition has carried consumer input, including the 2 made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| ranolazine Stable angina pectoris in patients on maximum tolerated doses of beta-blocker or calcium channel blocker where revascularisation is not an option and… | Mar 2018 | Recommended with restriction | unclear |
| ranolazine Add-on symptomatic treatment of stable angina pectoris in patients with inadequate symptom control despite taking the maximum tolerated dose of a beta-blocker… | Mar 2017 | Not recommended | none received |
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| nicorandilAPO-NICORANDIL nicorandil 10 mg tablet blister pack | 2014 | 6 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.